HPS Pharmacies prides itself on providing innovative and informative support to assist in the diverse range of issues health professionals face on a day-to-day basis, and to facilitate the distribution of this information for a variety of sectors within the healthcare industry.
HPS’ clinical articles are written by HPS Pharmacies’ experienced and knowledgeable staff and are peer-reviewed by specialist leaders in their field to ensure the accuracy of the information provided. The resourceful and diverse range of articles play an integral role in keeping all health professionals up-to-date with the happenings throughout the industry on a regular basis.
Chronic obstructive pulmonary disease (COPD) is estimated to affect around 5% of people over 45 years of age, yet accounts for over half of the disease burden due to respiratory conditions. This progressive condition…
Read more
Erythropoiesis-stimulating agents (ESAs) are used to promote the production of erythrocytes. This medication group includes recombinant human erythropoietin (EPO) derivatives (e.g. epoetin alfa, epoetin beta, and epoetin lambda) and chemically modified forms of EPO…
Read more
The thyroid gland produces three hormones, thyroxine (T4), triiodothyronine (T3), and calcitonin. Thyroxine is the main hormone produced by the thyroid gland. While triiodothyronine is the more active form, the majority of this hormone…
Read more
What is rheumatoid arthritis? Rheumatoid arthritis (RA) is a chronic inflammatory disorder that affects the joints and can damage other body systems, including the skin, eyes, lungs, heart, and blood vessels. Unlike the wear-and-tear…
Read more
Finerenone is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of chronic kidney disease (CKD) with type II diabetes. Finerenone is a mineralocorticoid receptor antagonist. The mineralocorticoid receptor plays an important…
Read more
Immunotherapy and targeted treatment of melanoma have drastically improved prognosis. Well established in the metastatic melanoma setting, studies have proven PD1 inhibition in the adjuvant setting for high-risk resectable melanoma, and this is now…
Read more
